PE-22-28 Guide

PE-22-28 is a synthetic peptide derived from Spadin that blocks TREK-1 potassium channels in hippocampal serotonin pathways. Unlike SSRIs which block reuptake transporters over weeks, PE-22-28 directly gates TREK-1 channels to acutely increase serotonergic tone — showing antidepressant effects in animal models within 4 days, compared to 3–4 weeks for conventional antidepressants.

PE-22-28 is a synthetic analog of Spadin, a naturally occurring peptide fragment of pro-sortilin that was discovered to block TREK-1 (TWIK-related potassium channel 1) — a two-pore domain potassium channel in the K2P family. TREK-1 channels are predominantly expressed in the dorsal raphe nucleus and hippocampus, where they regulate serotonin neurotransmission by controlling the excitability of serotonergic neurons.

Research by Michel Lazdunski's group at CNRS France found that TREK-1 knockout mice displayed resistant antidepressant-like behavior across multiple behavioral tests — suggesting that TREK-1 normally suppresses serotonin release. Blocking TREK-1 pharmacologically should therefore mimic this antidepressant state. Spadin and its optimized derivative PE-22-28 were developed as selective TREK-1 blockers to test this hypothesis.

In preclinical studies, PE-22-28 showed antidepressant effects in forced swim tests and learned helplessness models within 4 days of daily dosing — dramatically faster than the 3–4 week onset required by SSRIs. It also demonstrated neurogenesis-promoting effects in the hippocampus (a mechanism shared with chronic SSRI treatment) without the sexual dysfunction, weight gain, or discontinuation syndrome associated with SSRIs. Human clinical trial data is currently absent.

TREK-1 channels are mechanosensitive potassium channels that hyperpolarize serotonergic neurons when open — reducing their firing rate and serotonin release. PE-22-28 blocks these channels, allowing serotonergic neurons to maintain higher tonic firing rates. This directly increases serotonin release in the hippocampus and prefrontal cortex without receptor desensitization or reuptake inhibition.

SSRIs require weeks to produce clinically meaningful serotonin increases because initial SERT blockade triggers auto-receptor feedback that reduces serotonin neuron firing. As 5-HT1A autoreceptors desensitize over weeks, the full antidepressant effect emerges. PE-22-28 bypasses this delay entirely — no autoreceptor desensitization is required because it increases serotonin through a different node in the circuit.

Like chronic SSRI treatment, PE-22-28 promotes adult hippocampal neurogenesis in animal studies — increasing BrdU-positive proliferating cells in the dentate gyrus subgranular zone. This neurogenic effect correlates with antidepressant behavioral outcomes in animal models and may underlie the longer-lasting mood regulation seen beyond the immediate serotonin effects of TREK-1 blockade.

Beyond depression models, PE-22-28 shows anxiolytic properties in open field and elevated plus maze tests. TREK-1 channels are also expressed in amygdala circuits that regulate fear and anxiety responses. PE-22-28's channel-blocking action in these regions appears to reduce amygdala hyperreactivity — complementing its serotonin-enhancing effects in depression circuits for a dual antidepressant-anxiolytic profile.

TREK-1 Channel Blockade: TREK-1 channels are mechanosensitive potassium channels that hyperpolarize serotonergic neurons when open — reducing their firing rate and serotonin release. PE-22-28 blocks these channels, allowing serotonergic neurons to maintain higher tonic firing rates. This directly increases serotonin release in the hippocampus and prefrontal cortex without receptor desensitization or reuptake inhibition.

Fast Serotonin Increase: SSRIs require weeks to produce clinically meaningful serotonin increases because initial SERT blockade triggers auto-receptor feedback that reduces serotonin neuron firing. As 5-HT1A autoreceptors desensitize over weeks, the full antidepressant effect emerges. PE-22-28 bypasses this delay entirely — no autoreceptor desensitization is required because it increases serotonin through a different node in the circuit.

Hippocampal Neurogenesis: Like chronic SSRI treatment, PE-22-28 promotes adult hippocampal neurogenesis in animal studies — increasing BrdU-positive proliferating cells in the dentate gyrus subgranular zone. This neurogenic effect correlates with antidepressant behavioral outcomes in animal models and may underlie the longer-lasting mood regulation seen beyond the immediate serotonin effects of TREK-1 blockade.

Anxiety Reduction: Beyond depression models, PE-22-28 shows anxiolytic properties in open field and elevated plus maze tests. TREK-1 channels are also expressed in amygdala circuits that regulate fear and anxiety responses. PE-22-28's channel-blocking action in these regions appears to reduce amygdala hyperreactivity — complementing its serotonin-enhancing effects in depression circuits for a dual antidepressant-anxiolytic profile.

Human dose data is limited — these protocols are derived from animal study scaling. Intranasal administration may improve CNS penetration. Use Shotlee to track mood, anxiety, sleep, and energy over your protocol to detect response patterns.